Clinical Trials Browser

Interventional × Oxaliplatin × Lymphoid × Clear all

NCT03418038 2026-04-16

Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia

Phase 2 Recruiting

LymphoidOther hematologic neoplasm

Hodgkin Disease, Lymphoma, Leukemia, Myelomonocytic, Chronic, Lymphoma, Large B-Cell, Diffuse

NCT03321643 2026-04-13

Testing the Addition of an Immunotherapy Agent, Atezolizumab, When Given With the Usual Chemo-Immunotherapy Drug Combination (Rituximab Plus Gemcitabine and Oxaliplatin) for Relapsed/Refractory (That Has Come Back or Not Responded to Treatment) Transformed Diffuse Large B-Cell Lymphoma

Phase 1 Active not recruiting

Lymphoma, Large B-Cell, Diffuse

NCT04542824 2026-04-08

EPCORE™ NHL-3

Phase 1/2 Active not recruiting

LymphoidOther hematologic neoplasm

Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone

NCT04663347 2026-04-08

EPCORE™ NHL-2

Phase 1/2 Active not recruiting

Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse

NCT06508658 2026-04-08

EPCORE DLBCL-4

Phase 3 Active not recruiting

Lymphoma, Large B-Cell, Diffuse

NCT04408638 2026-04-07

A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combination With Gemcitabine + Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Phase 3 Active not recruiting

Lymphoma, Large B-Cell, Diffuse

NCT05139017 2026-04-07

waveLINE-003

Phase 2/3 Recruiting

Lymphoma, Large B-Cell, Diffuse

NCT06624085 2026-04-02

A Study Evaluating the Safety and Efficacy of Glofitamab + Gemcitabine + Oxaliplatin in U.S. Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Phase 1 Recruiting

Lymphoma

NCT07409428 2026-04-01

A Phase III Study of HMPL-760 Plus R-GemOx VS Placebo Plus R-GemOx in Relapsed/Refractory DLBCL

Phase 3 Recruiting

Lymphoma, Large B-Cell, Diffuse

NCT07451652 2026-04-01

Low Dose Epcoritamab Plus GemOx in R/R DLBCL

Phase 2 Recruiting

Lymphoma, Large B-Cell, Diffuse

NCT06806033 2026-03-31

A Study to Evaluate the Optimization of the Cytokine Release Syndrome Profile for Glofitamab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed/Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma

Phase 2 Recruiting

Cytokine Release Syndrome, Lymphoma, Non-Hodgkin, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT04384484 2026-03-24

LOTIS 5

Phase 3 Active not recruiting

Lymphoma, Lymphoma, Large B-Cell, Diffuse

NCT07480850 2026-03-18

Efficacy and Safety of Glofitamab Combined With GemOxin the Treatment of Refractory Diffuse Large B-Cell Lymphoma

Phase 2 Active not recruiting

Lymphoma, Large B-Cell, Diffuse

NCT05171647 2026-03-06

SUNMO

Phase 3 Active not recruiting

208 enrolled 12 charts

Lymphoma, Non-Hodgkin

NCT05700448 2026-02-05

Study of Sugemalimab (or Placebo) Plus PGemOx Regimen in Participants With Extranodal NK/T-Cell Lymphoma

Phase 3 Not yet recruiting

Lymphoma, Extranodal NK-T-Cell

NCT07365306 2026-01-26

Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Phase 2 Not yet recruiting

Lymphoma, Large B-Cell, Diffuse

NCT04182204 2025-12-22

POLARGO

Phase 3 Completed

270 enrolled 36 charts

Lymphoma, Lymphoma, Large B-Cell, Diffuse

NCT06929624 2025-11-18

A Phase 3 Clinical Study of SHR-A1912 Combined With R-GemOx Versus R-GemOx in Diffuse Large B-cell Lymphoma

Phase 3 Recruiting

Lymphoma, Large B-Cell, Diffuse

NCT04607772 2025-10-03

Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL)

Phase 1/2 Withdrawn

Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT06905509 2025-09-29

Epcoritamab Plus Standard of Care Platinum-Based Chemotherapy and Autologous Hematopoietic Cell Transplant for the Treatment of Relapsed or Refractory Large B-cell Lymphoma

Phase 2 Recruiting

Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone

NCT07081022 2025-08-21

JS203 Combination Regimens in B-Cell Non-Hodgkin's Lymphoma

Phase 2 Recruiting

Lymphoma, B-Cell

NCT07124936 2025-08-15

A Study of HDM2005 in Combination With Standard of Care in Patients With Diffuse Large B-Cell Lymphoma

Phase 1/2 Recruiting

Lymphoma, Large B-Cell, Diffuse

NCT05279300 2025-08-11

A Study of CS5001 in Patients With Advanced Solid Tumors and Lymphomas

Phase 1 Recruiting

LymphoidOther solid neoplasm

Advanced Solid Tumor

NCT04984837 2025-08-01

Study of Lacutamab in Peripheral T-cell Lymphoma

Phase 2 Recruiting

Recurrence, Lymphoma, T-Cell, Lymphoma, T-Cell, Peripheral

NCT07001540 2025-06-19

Evaluation of the Efficacy and Safety of Polatuzumab Vedotin Combined With Rituximab, Gemcitabine, and Oxaliplatin (Pola-R-GemOx) as Salvage Therapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Patients Ineligible for Autologous Transplantation

Phase 2 Recruiting

Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT02953509 2025-05-29

Trial of Magrolimab (Hu5F9-G4) in Combination With Rituximab or Rituximab + Chemotherapy in Participants With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma

Phase 1/2 Terminated

178 enrolled 33 charts

Lymphoma, Non-Hodgkin

NCT06854445 2025-03-24

Clinical Trial of TQB2825 Injection Combined With Chemotherapy in Subjects With Diffuse Large B-cell Lymphoma

Phase 2 Recruiting

Lymphoma, Large B-Cell, Diffuse

NCT03169790 2025-02-24

QUILT-3.052: NANT Non-Hodgkin Lymphoma (NHL) Vaccine: Combination Immunotherapy in Subjects With Relapsed CD20-positive NHL

Phase 1/2 Withdrawn

Lymphoma, Non-Hodgkin

NCT06792253 2025-01-24

Study Comparing BEBT-908 Combined With R to SOC for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Phase 3 Recruiting

Lymphoma, Large B-Cell, Diffuse

NCT02692248 2024-10-10

Ibrutinib in Patients With Refractory/Relapsed Non-GCB Diffuse Large B-cell Lymphoma Non-candidates to ASCT

Phase 2 Completed

64 enrolled 17 charts

Lymphoma, Large B-Cell, Diffuse

NCT02348216 2024-06-04

ZUMA-1

Phase 1/2 Completed

307 enrolled 41 charts

Lymphoma, Large B-Cell, Diffuse

NCT01626664 2024-04-25

KW-0761 or Investigator's Choice in Subjects With Previously Treated Adult T-cell Leukemia-Lymphoma (ATL)

Phase 2 Completed

71 enrolled 15 charts

LymphoidOther hematologic neoplasm

Leukemia-Lymphoma, Adult T-Cell, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT04313608 2024-03-25

A Study Evaluating the Safety and Efficacy of Glofitamab or Mosunetuzumab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and High-Grade Large B-Cell Lymphoma

Phase 1 Completed

23 enrolled 17 charts

Lymphoma, B-Cell

NCT03878524 2024-03-04

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

Phase 1 Terminated

BreastClassical hematologyGastrointestinalGenitourinaryLymphoidMyeloidOther hematologic neoplasmPlasma cell

Anemia, Blast Crisis, Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Thrombocytosis, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

NCT06164327 2023-12-11

Study of BEBT-908 Combined With Drugs in the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Phase 1 Unknown

Lymphoma, Large B-Cell, Diffuse

NCT04022005 2023-09-11

Chidamide + R-GemOx Regimen as Salvage Treatment for Transplant-ineligible Patients With Relapsed/Refractory DLBCL

Phase 2 Completed

Lymphoma, Large B-Cell, Diffuse

NCT03422523 2022-08-22

ARGO

Phase 2 Terminated

Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT03488251 2022-08-16

PK,PD,Safety and Tolerability of Multiple Dose Regimens of MT-3724 With Gemcitabine and Oxaliplatin for the Treatment of Patients With Relapsed/Refractory Diffuse Large B Cell Non-Hodgkin's Lymphoma

Phase 2 Terminated

8 enrolled 9 charts

Lymphoma, Large B-Cell, Diffuse

NCT05186558 2022-03-07

Penpulimab Plus R2-GemOx Regimen in Relapsed or Refractory DLBCL

Phase 2 Unknown

Neoplasms by Histologic Type, Lymphoma, Large B-Cell, Diffuse

NCT05254899 2022-02-24

Anti-PD-1 Antibody and P-GEMOX Chemotherapy Combined With Radiotherapy in High-risk Early-Stage ENKTL

Phase 2 Unknown

Lymphoma, Extranodal NK-T-Cell

NCT02741388 2021-12-07

SELINDA

Phase 1 Completed

Lymphoma, Lymphoma, B-Cell

NCT02085655 2021-03-15

PEG-ASP+Gemox Regimen and Thalidomide for NK/T Lymphoma

Phase 3 Unknown

Lymphoma, Extranodal NK-T-Cell

NCT02951156 2020-12-17

Javelin DLBCL

Phase 3 Terminated

29 enrolled 24 charts

Lymphoma, Large B-Cell, Diffuse

NCT02181218 2020-11-17

Phase I Study of Romidepsin, Gemcitabine, Oxaliplatin, and Dexamethasone in Patients With Relapsed/Refractory Aggressive Lymphomas

Phase 1 Completed

DermatologicLymphoid

Hodgkin Disease, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral

NCT00436280 2020-08-06

Chemotherapy for Participants With Lymphoma

Phase 2 Completed

68 enrolled 20 charts

Lymphoma, Large B-Cell, Diffuse

NCT04500561 2020-08-05

YY-20394 、GEMOX Treatment Diffuse Large B-cell Lymphoma Single Arm, Open, Multicentrized Phase 1b/2 Clinical Trial

Phase 1/2 Unknown

Lymphoma, Large B-Cell, Diffuse

NCT04432402 2020-06-16

Lenalidomide in Combination With R-GemOx in First-line Treatment of Elderly Diffuse Large B Cell Lymphoma

Phase NA Unknown

Lymphoma, Large B-Cell, Diffuse

NCT02918747 2020-01-28

PEG-ASP+Gemoxd vs. PEG-ASP+CHOP as First-line Chemotherapy to Treatment NK/T-cell Lymphoma With Early Stage

Phase 2 Unknown

Lymphoma

NCT04239170 2020-01-23

Camrelizumab(SHR-1210) Combined With GEMOX in Patients With Relapsed or Refractory Hodgkin Lymphoma

Phase 2 Unknown

Hodgkin Disease

NCT00166439 2020-01-14

Trial of Oxaliplatin, Cytosine Arabinoside, Dexamethasone With Rituxan (ROAD) in Patients With Relapsed Non-Hodgkins Lymphoma

Phase 2 Completed

50 enrolled 8 charts

Lymphoma